3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors

Abstract

Novel substituted quinazoline compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

1 . A compound of the formula:  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  is a phenyl, naphth-1-yl, naphth-2-yl, heterocyclic or heteroaryl ring, which ring is optionally substituted independently by one or more substituents selected from halogen, C 1-4  alkyl, halo-substituted-C 1-4  alkyl, cyano, nitro, (CR 10 R 20 ) v NR 4 R 14 , (CR 10 R 20 ) v C(Z)NR 4 R 14 , (CR 10 R 20 ) v C(Z)OR 8 , (CR 10 R 20 ) v COR 3 , (CR 10 R 20 ) v C(O)H, SR 5 , S(O)R 5 , S(O) 2 R 5 , (CR 10 R 20 ) v OR 8 , ZC(Z)R 11 , NR 10 C(Z)R 11 , or NR 10 S(O) 2 R 7 ;  
 R 2  is a C 1-10  alkyl, C 3-7  cycloalkyl, C 3-7 cycloalkylC 1-10  alkyl, C 5-7  cycloalkenyl, C 5-7  cycloalkenyl C 1-10  alkyl, aryl, arylC 1-10  alkyl, heteroaryl, heteroarylC 1-10  alkyl, heterocyclic, or heterocyclylC 1-10  alkyl moiety, which moiety is optionally substituted one or more times independently with C 1-10  alkyl, halo-substituted C 1-10  alkyl, C 2-10  alkenyl, C 2-10  alkynyl, C 3-7  cycloalkyl, C 3-7 cycloalkylC 1-10  alkyl, C 5-7  cycloalkenyl, C 5-7  cycloalkenyl C 1-10  alkyl, halogen, (CR 10 R 20 ) n OR 6 , (CR 10 R 20 ) n SH, (CR 10 R 20 ) n S(O) m R 7 , (CR 10 R 20 ) n NHS(O) 2 R 7 , (CR 10 R 20 ) n NR 4 R 14 , (CR 10 R 20 ) n CN, (CR 10 R 20 ) n S(O) 2 NR 4 R 14 , (CR 10 R 20 ) n C(Z)R 6 , (CR 10 R 20 ) n OC(Z)R 6 , (CR 10 R 20 ) n C(Z)OR 6 , (CR 10 R 20 ) n C(Z)NR 4 R 14 , (CR 10 R 20 ) n NR 10 C(Z)R 6 , (CR 10 R 20 ) n NR 10 C(═NR 10 ) NR 4 R 14 , (CR 10 R 20 ) n OC(Z)NR 4 R 14 , (CR 10 R 20 ) n NR 10 C(Z)NR 4 R 14 , or (CR 10 R 20 ) n NR 10 C(Z)OR 7 ;  
 R 3  is a C 1-4  alkyl, halo-substituted C 1-4  alkyl, C 2-4  alkenyl, C 2-4  alkynyl, C 3-7  cycloalkyl, C 5-7  cycloalkenyl, aryl, arylC 1-4  alkyl, heteroaryl, heteroarylC 1-4  alkyl, heterocyclyl, heterocyclylC 1-4  alkyl, (CR 10 R 20 ) v OR 7 , (CR 10 R 20 ) v S(O) m R 7 , (CR 10 R 20 ) v NHS(O) 2 R 7 , or (CR 10 R 20 ) v NR 4 R 14;  and wherein the aryl, arylalkyl, heteroaryl, or heteroaryl alkyl may be optionally substituted;  
 R 4  and R 14  is each independently selected from hydrogen or optionally substituted C 1-4  alkyl, optionally substituted aryl or optionally substituted aryl-C 1-4  alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR 9 ;  
 R 5  is hydrogen, C 1-4  alkyl, C 2-4  alkenyl, C 2-4  alkynyl or NR 4 R 14 , excluding the moieties SR 5  being SNR 4 R 14 , S(O) 2 R 5  being SO 2 H and S(O)R 5  being SOH;  
 R 6  is hydrogen, C 1-10  alkyl, C 3-7  cycloalkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, aryl, arylC 1-10  alkyl, heteroaryl or heteroarylC 1-10  alkyl, wherein these moieties may be optionally substituted;  
 R 7  is a C 1-6 alkyl, aryl, arylC 1-6 alkyl, heterocyclic, heterocyclylC 1-6  alkyl, heteroaryl, or heteroarylC 1-6 alkyl moiety; and wherein each of these moieties may be optionally substituted;  
 R 8  is hydrogen, C 1-4  alkyl, halo-substituted C 4  alkyl, C 2-4  alkenyl, C 2-4  alkynyl, C 3-7  cycloalkyl, C 5-7  cycloalkenyl, aryl, arylC 1-4  alkyl, heteroaryl, heteroarylC 1-4  alkyl, heterocyclyl, heterocyclylC 1-4  alkyl, (CR 10 R 20 ) t OR 7 , (CR 10 R 20 ) t S(O) m R 7 , (CR 10 R 20 ) t NHS(O) 2 R 7 , or (CR 10 R 20 ) t NR 4 R 14 ; and wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl may be optionally substituted;  
 R 9  is hydrogen, C(Z)R 6  or optionally substituted C 1-10  alkyl, optionally substituted aryl or optionally substituted aryl-C 1-4  alkyl;  
 R 10  and R 20  are each independently selected from hydrogen or C 1-4  alkyl;  
 R 11  is a C 1-4  alkyl, halo-substituted C 1-4  alkyl, C 2-4  alkenyl, C 2-4  alkynyl, C 3-7  cycloalkyl, C 5-7  cycloalkenyl, aryl, arylC 1-4  alkyl, heteroaryl, heteroarylC 1-4  alkyl, heterocyclyl, heterocyclylC 1-4  alkyl, (CR 10 R 20 ) t OR 7 , (CR 10 R 20 ) t S(O) m R 7 , (CR 10 R 20 ) t NHS(O) 2 R 7 , or (CR 10 R 20 ) v NR 4 R 14 ; and wherein the aryl, arylalkyl, heteroaryl, or heteroaryl alkyl may be optionally substituted;  
 Z is oxygen or sulfur;  
 n is 0, or an integer having a value of 1 to 10;  
 m is 0, or the integer 1 or 2;  
 v is 0, or an integer having a value of 1 or 2;  
 t is an integer having a value of 1 to 3;  
 or a pharmaceutically acceptable salt thereof.  
 
     
     
         2 . The compound according to  claim 1  wherein R 1  is an optionally substituted phenyl or napthyl.  
     
     
         3 . The compound according to  claim 2  wherein the substituent is independently selected from halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.  
     
     
         4 . The compound according to  claim 3  wherein the substituent is a halogen.  
     
     
         5 . The compound according to  claim 1  wherein R 2  is an optionally substituted aryl, arylalkyl, C 3-7  cycloalkyl, heteroarylC 1-10  alkyl, or heterocyclylC 1-10  alkyl.  
     
     
         6 . The compound according to  claim 5  wherein R 2  is an optionally substituted phenyl, benzyl, phenethyl, cyclohexyl, pyrrolindylmethyl, morpholino ethyl, morpholinopropyl, C 1-4  alkyl, or pyridylethyl.  
     
     
         7 . The compound according to  claim 5  wherein the substitutent is independently halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.  
     
     
         8 . The compound according to  claim 6  wherein the substituent is a halogen, or alkyl.  
     
     
         9 . The compound according to  claim 1  which is: 
 1,5-Diphenyl-3,4-dihydro-(1H)-quinazolin-2-one;    1-(2,6-Difluorphenyl)-5-phenyl-3,4-dihydro-(1H)-quinazolin-2-one;    1-Phenyl-5-(2-methylphenyl)-3,4-dihydro-(1H)-quinazolin-2-one; or a pharmaceutically acceptable salt thereof.    
     
     
         10 . A pharmaceutical composition comprising an effective amount of a compound according to  claim 1  and a pharmaceutically acceptable carrier or diluent.  
     
     
         11 . A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound of Formula (I) according to  claim 1 .  
     
     
         12 . The method according to  claim 11  wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, meningitis, ischemic and hemorrhagic stroke, neurotrauma/open or closed head injury, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac, brain and renal reperfusion injury, thrombosis, glomerulamephritis, chronic renal failure, diabetes, diabetic retinopathy, macular degeneration, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, neurodegenrative disease, muscle degeneration, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, eczema, contact dermatitis, psoriasis, sunburn, or conjunctivitis.  
     
     
         13 . A method of treating the common cold or respiratory viral infection caused by human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus in a human in need thereof which method comprises administering to said human an effective amount of a compound of Formula (I) according to  claim 1 .  
     
     
         14 . The method according to  claim 13  wherein the respiratory viral infection exacerbates asthma, chronic bronchitis, chronic obstructive pulmonary disease, otitis media, or sinusitis.  
     
     
         15 . A method of treatment, including prophylaxis, of smoke induced airway inflammation in a human in need thereof, which comprises administering to said human an effective amount of a compound according to  claim 1 .  
     
     
         16 . The method according to  claim 15  wherein the smoke induced airway inflammation is caused by inhalation of cigarette smoke, inhalation of smoke produced from a burning plant material, or inhalation of burning smoke from fossil fuels.  
     
     
         17 . The method according to  claim 15  wherein the smoke induced airway inflammation exacerbates a pre-existing asthmatic condition, a pre-existing chronic bronchitis, or pre-existing chronic obstructive pulmonary disease in said human.  
     
     
         18 . A method of treatment, including prophylaxis, for inflammation enhanced cough in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to  claim 1 .  
     
     
         19 . The method according to  claim 18  wherein the inflammation enhanced cough is cough variant asthma, or eosinophilic bronchitis.  
     
     
         20 . The method according to  claim 13  wherein the compound of Formula (I) is administered with a second therapeutic agent.  
     
     
         21 . The method according to  claim 20  wherein the second therapeutic agent is an anti-tussive; an antihistamine; a steroid; a PDE 4  agent, an antibiotic; an anti-inflammatory agent selected from an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin; an antiviral agent ribavirin, amantidine, rimantidine, Pleconaril, AG 7088, or BTA-188; a decongestant; an influenza neuraminidase inhibitor selected from zamanivar (Relenza), oseltamivir (Tamiflu) or RWJ-270201.  
     
     
         22 . The method according to  claim 13  wherein the compound of Formula (I) is administered orally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation.